2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 53, “ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults With Beta-Thalassemia: Preliminary Results From a Phase II Study,” presented by Antonio G. Piga, MD.
James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Bertrand Coiffier, MD, PhD, of the Centre Hospitalier Lyon-Sud discuss three French studies on rituximab maintenance vs wait and watch after R-DHAP in mantle cell lymphoma; R-CHOP with or without radiotherapy in diffuse large B-cell lymphoma; and romidepsin and CHOP in peripheral T-cell lymphoma.
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 6, "Sorafenib vs Placebo in Addition to Standard Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial," presented by Christoph Röllig, MD.
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 7, “A Randomized Comparison of Daunorubicin 90 mg/m2 vs 60 mg/m2 in AML Induction: Results From the UK NCRI AML17 Trial in 1206 Patients,” presented by Alan K. Burnett, MD.
Time: 1:29
Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 379, “BLAST: A Confirmatory, Single-Arm, Phase II Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE) Antibody Construct, in Patients With Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia,” and abstract 3704, “An Evaluation of Molecular Response in a Phase II Open-Label, Multicenter Confirmatory Study in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Receiving Treatment With the BiTE Antibody Construct Blinatumomab,” presented by Nicola Gökbuget, MD.
Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 380, “T Cells Engineered with a Chimeric Antigen Receptor (CAR)-Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children With Relapsed, Refractory ALL,” presented by Stephan A. Grupp, MD, PhD; abstract 381, “Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia,” presented by Daniel W. Lee III, MD; and abstract 382, “CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients With Relapsed, Refractory B-Cell ALL,” presented by Jae H. Park, MD.
